A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM - CSF - secreting
Breast Tumor Vaccine for HER - 2 + Metastatic Breast Cancer.
«
Personalized tumor vaccine shows promise in pilot trial: Vaccine against patients» own tumors triggers a broad response, and induced five - year remission in one patient with advanced ovarian cancer.»
We are leaders in the field of cancer immunotherapy and the development
of tumor vaccines and new antibodies, working to activate the human body's own immune system to fight cancer.
Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte - macrophage colony - stimulating factor - secreting
breast tumor vaccine: a chemotherapy dose - ranging study of safety and immune activation.
It is also a whole -
tumor vaccine, meant to stimulate an immune response against not just one tumor - associated target but hundreds or thousands.